LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M

LeonaBio, Inc.

Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.
Cash and investments $88.3M at Dec 31, 2025, up from $51.3M year-end 2024; $90M private placement closed with potential $146M from warrant exercises.
Exclusive global license acquired for Phase 3 lasofoxifene (SERM) for ESR1-mutated metastatic breast cancer; ELAINE-3 enrollment completion expected 4Q2026, topline data 2H2027.
ATH-1105 Phase 2 proof-of-concept trial in ALS patients on track to initiate in 2H2026; Phase 1 data showed favorable safety and CNS penetration.
G&A expenses decreased to $16.7M from $26.1M, reflecting cost efficiencies; company renamed from Athira to LeonaBio in Jan 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LeonaBio, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.